Drug Developement/Delivery
- Advances in Antibody-Targeted Lipid Nanoparticles (Ab-LNPs) and Their Emerging Therapeutic Applications
- Antibody-Oligonucleotide Conjugates (AOCs): Recent Advances
- Molecular Glue-Antibody Conjugates (MACs)
- FDA Approval of Semaglutide for MASH - Other Promisiong Pipelines Ahead
- Key Advances in Breast Cancer Treatment: First Half of 2025
- BMS-986238: A New Macrocyclic Peptide-Based PD-L1 Inhibitor
- Camptothecin & Its Derivatives for Cancer Therapy
- FDA Approves First NASH Drug & Other Pipelines in Clinical Trials
- Advances in Macrocyclic Peptide Drug Development
- Upcoming GLP-1 RAs for NASH: A Comprehensive List
